Minerva Neurosciences Inc NERV.OQ NERV.O is expected to show no change in quarterly revenue when it reports results on February 23 (estimated) for the period ending December 31 2025
LSEG's mean analyst estimate for Minerva Neurosciences Inc is for a loss of 30 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The average consensus recommendation for the biotechnology & medical research peer group is also "Hold".
Wall Street's median 12-month price target for Minerva Neurosciences Inc is $4.50, about 29% below its last closing price of $6.34
This summary was machine generated February 20 at 13:43 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)